The global cannabinoids market was valued at USD 36 billion in 2025. The market is projected to grow from USD 41 billion in 2026 to USD 113.6 billion by 2034, exhibiting a compound annual growth rate of 13.59% during the forecast period. Contrive Datum Insights presents this information in its report titled "Cannabinoids Market Size, Share & Industry Analysis, By Cannabinoid type (Cannabidiol (CBD), Tetrahydrocannabinol (THC), Cannabigerol (CBG), Cannabinol (CBN), Cannabichromene (CBC), Cannabidiolic Acid (CBDA), Other Cannabinoids), Source (Hemp-Derived, Marijuana-Derived, Synthetic, Semi-Synthetic (Converted)), Product form (Isolate, Distillate, Crude Extract, Oils and Tinctures, Capsules and Softgels, Edibles, Topicals, Vapes and Inhalables), Extraction method (CO2 Extraction, Solvent Extraction, Solventless Extraction, Chemical Synthesis and Biosynthesis), Application (Pharmaceuticals, Nutraceuticals and Dietary Supplements, Food and Beverages, Cosmetics and Personal Care, Recreational and Adult Use, Pet and Veterinary Products, Research and Others), Spectrum profile (Full-Spectrum, Broad-Spectrum, Isolate (Single Molecule)), Purity grade (Pharmaceutical Grade, Food and Nutraceutical Grade, Cosmetic Grade, Industrial and Research Grade), Route of administration (Oral, Topical and Transdermal, Inhalation, Oromucosal Spray, Others), Distribution channel (Pharmacies and Drug Stores, Licensed Dispensaries, Online and E-commerce, Specialty and Health Stores, Business-to-Business Bulk Supply), Legal status (Prescription (Approved Drugs), Medical Cannabis Programmes, Adult-Use Regulated, Hemp-Derived Consumer Wellness), and Regional Forecast, 2026-2034".
Cannabinoids are the active compounds of the cannabis and hemp plants, supplied as isolated molecules, distillates and extracts, or produced by chemical synthesis and fermentation. They are sold as pharmaceutical ingredients and approved drugs, as nutraceutical and cosmetic ingredients, and as finished consumer products such as oils, capsules, edibles, topicals and inhalables. Buyers include drug makers, supplement and beverage brands, personal care companies, licensed retailers, pharmacies and patients under medical programmes.
Expanding pharmaceutical approvals and prescribing
Expanding pharmaceutical approvals and prescribing is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 13.59% a year, the cannabinoid type lines exposed to it move fastest: Cannabigerol (CBG) compounds at 22.97%, taking its share of revenue from 4% to 8.5% and its value from USD 1.44 billion to USD 9.66 billion.
Where the forecast could be beaten: faster approval of cannabinoid medicines, permissive US federal and EU rules for hemp-derived products, and wider reimbursement lift volumes while holding prices. The study puts that case at USD 132 billion in 2034, against USD 113.6 billion in the base.
Against that, restrictive hemp rules, persistent biomass oversupply and slow clinical adoption cut volumes and push realised prices lower. On that reading 2034 revenue stops at USD 82.6 billion. The weight of the problem sits in Cannabidiol (CBD): 55% of 2025 revenue growing at 11.33%, well under the market's 13.59%.
The Competitive Split Runs by Cannabinoid type
Suppliers here are separated by cannabinoid type, not by geography. The incumbent position is Cannabidiol (CBD): 55% of 2025 revenue, USD 19.8 billion, and still 46% in 2034. The contested position is Cannabigerol (CBG) at 22.97% growth. Few suppliers hold both, which is why a market of USD 36 billion supports as many participants as it does.
Other Findings in the Study
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Source | Hemp-Derived | 48% · USD 17.28 billion | Synthetic 19.92% |
| Product form | Oils and Tinctures | 27% · USD 9.72 billion | Vapes and Inhalables 22.72% |
| Extraction method | Solvent Extraction | 42% · USD 15.12 billion | Solventless Extraction 18.85% |
| Application | Pharmaceuticals | 30% · USD 10.8 billion | — |
| Spectrum profile | Full-Spectrum | 46% · USD 16.56 billion | Broad-Spectrum 14.83% |
| Purity grade | Food and Nutraceutical Grade | 46% · USD 16.56 billion | Pharmaceutical Grade 18.45% |
| Route of administration | Oral | 44% · USD 15.84 billion | Oromucosal Spray 16.47% |
| Distribution channel | Licensed Dispensaries | 30% · USD 10.8 billion | Online and E-commerce 16.23% |
| Legal status | Hemp-Derived Consumer Wellness | 34% · USD 12.24 billion | Prescription (Approved Drugs) 17.95% |
- Regionally, the lead sits with North America: 40% of 2025 global revenue, USD 14.4 billion rising to USD 38.62 billion in 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 20% in 2025 to 26% in 2034, with revenue growing from USD 7.2 billion to USD 29.54 billion.
- Middle East and Africa remains the smallest region throughout, at 7% of 2025 revenue and 7% by 2034.
- Cannabidiol (CBD) was the leading cannabinoid type line in 2025, taking 55% of revenue at USD 19.8 billion.
- The fastest cannabinoid type line is Cannabigerol (CBG), forecast to compound at 22.97% through the period.
- The United States is the largest single country market at USD 12.6 billion in 2025, 35% of global revenue.
The report segments the market across ten axes; by cannabinoid type, and by source, product form, extraction method, application, spectrum profile, purity grade, route of administration, distribution channel and legal status; with revenue and a growth rate for every line in every year from 2020 to 2034, alongside bear, base and bull scenarios for the headline total at USD 82.6 billion and USD 132 billion by 2034. It covers all five regions with country-level breakdowns, the competitive landscape, and the research methodology behind every estimate. Delivered as a PDF; a free sample is available on request.